Paysign, Inc. reported second quarter 2026 financial results on August 5, 2026, announcing record revenue of $28.3 million, a 48% increase year-over-year. The company raised its full-year 2026 revenue outlook to $114.0–$117.0 million and adjusted EBITDA guidance to $35.0–$38.0 million. GAAP net income reached $6.76 million, or $0.11 per diluted share, driven by an 89% surge in pharmaceutical revenue and a 21% increase in plasma revenue. Operating margin expanded significantly to 24.8%, up from 7.5% in the prior year period. The company exited the quarter with $27.37 million in unrestricted cash and zero bank debt. Paysign operates in the fintech healthcare sector, providing patient affordability solutions, donor compensation platforms, and integrated payment processing for the life sciences industry.